<DOC>
	<DOCNO>NCT02922452</DOCNO>
	<brief_summary>This study evaluate effect dilitazem single-dose PK BMS-986141 parameter like Cmax , AUC ( INF ) , AUC ( 0-T ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Diltiazem Pharmacokinetics ( PK ) BMS-986141 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diltiazem</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Healthy men woman ( child bear potential ) determine medical history , surgical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory test include coagulation parameter . 3 . Subjects body mass index 18 32 kg/m2 , inclusive . 4 . Women participant must document proof childbearing potential . 5 . Men sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment BMS986141 plus 5 halflives plus 90 day total 100 day posttreatment completion . 1 . Acute chronic medical illness , subject bleed diathesis , gastrointestinal ulcer , hepatic disease . 2 . History nausea , diarrhoea , recent surgery , use tobacco nicotine containing product , drug alcohol use , important arrhythmia , sinus bradycardia , chronic headache , history multiple event dizziness , periodontal disease recent blood donation . 3 . Prior exposure BMS986141 prothrombin complex , investigational product placebo within 4 week study treatment start , prescription counter drug except clear BMS clinical monitor . 4 . History allergy BMS986141 , dilitazem significant drug allergy adverse reaction anticoagulant antiplatelets . 5 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECGs , clinical laboratory determination beyond consistent target population</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>